Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
In summary, available data demonstrate that IL-1 and TNF are the causative agents underlying the bone loss induced by estrogen deficiency. Indeed, these factors are produced in bone and the bone marrow, released in larger amounts from cells of estrogen-deficient subjects, and indispensable for reproducing the effects of estrogen deficiency in bone. These observations support the hypothesis that the bone sparing effect of estrogen is due to the ability of the hormone to block osteoclastogenesis, the activation of mature osteoclasts and, as recently demonstrated, the rate of apoptotic osteoclast death. Although IL-1 and TNF play a prominent causal role in these events, the bone-sparing effect of estrogen is mediated by numerous cytokines which, by simultaneously stimulating multiple target cells, induce effects that are not accounted for by any one single factor (Fig. 2). The ability of estrogen to regulate some, but not all, the cytokines involved in this process is not inconsistent with this hypothesis because cytokines have potent synergistic effects. Thus, a considerable increase in bone resorption may result from a relatively small increase in the concentration of only a few of the bone-resorbing factors present in the bone microenvironment. This concept is best illustrated by the study of Miyaura et al. demonstrating that the concentrations of either IL-1, IL-6, IL-6 receptor, or prostaglandins detected in the bone marrow of OVX mice are insufficient to account for the increased bone resorption caused by estrogen withdrawal. In contrast, the increase in bone resorption induced by OVX can be explained by the cumulative effects of these cytokines. Thus, a better understanding of the cooperative effects of cytokines and a recognition that the contribution of individual cytokines to postmenopausal bone loss varies with the passage of time after menopause are necessary to fully understand the mechanism of action of estrogen in bone. Although the relevance of individual bone-targeting cytokines in species specific, the development of transgenic mice with activatable or deactivatable promoters is likely to result in a further clarification of the integrated action of estrogen-regulated cytokines in human bone cells and lay the foundations for the use of cytokine inhibitors in the treatment of postmenopausal osteoporosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Estrogen acts via suppression of bone resorption [43–45]”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [44]
In the citing paper
“In addition, estrogen inhibits osteoclast formation by reducing the levels of other osteoclastogenic cytokines such as IL-1, IL-6, IL-11, TNF-α, TNF-β, and M-CSF [160, 161].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [160]
Citations
Cites
Interleukin-1 and interleukin-1 antagonism
Dinarello, C. (1991) · Blood · doi:10.1182/blood.v77.8.1627.1627 · Cited by 2,304
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B., Broxmeyer, H., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,442
Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D., & Mundy, G. R. (1986) · Nature · doi:10.1038/319516a0 · Cited by 1,434
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
An interleukin 1 like factor stimulates bone resorption in vitro
Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. B., & Russell, R. G. G. (1983) · Nature · doi:10.1038/306378a0 · Cited by 1,012
Modulation of Osteoclast Differentiation
SUDA, T., TAKAHASHI, N., & MARTIN, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 1,004 · cited 2×
“(22) These mice, which are cured by the administration of M-CSF,(3s) have an extra thymidine inserted within the coding region of the M-CSF gene, a mutation that generates a stop codon within the coding sequence,(3h) thereby resulting in the production of a defective M-CSF.(22) The formation of osteoclasts in bone mar…”
BackgroundSoluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.
Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., Koishihara, Y., Ohsugi, Y., Kumaki, K., & Taga, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11924 · Cited by 825
TURNER, R. T., RIGGS, B. L., & SPELSBERG, T. C. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-275 · Cited by 754
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.
Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G., Rodan, G. A., & Costantini, F. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06368.x · Cited by 749
Research works printed but not linked: 11
- Srivastava, 1995, Estrogen down-regulates the expression of M-CSF mRNA in bone marrow stromal cells by stimulating the production of the transcription factor EGR-1, J Bone Miner Res, 10, S18
- Matayoshi, 1995, Generation of human osteoclasts from peripheral blood cd 34+ cells, J Bone Miner Res, 10
- Pacifici, 1990, TNFα and GM-CSF secretion from human blood monocytes: Effect of menopause and estrogen replacement, J Bone Miner Res, 5, 145
- Kimble, 1996, Estrogen inhibits IL-1 and TNF gene expression in transfected murine macrophagic cells, J Bone Miner Res, 11
- Kaneki, 1991, The effect of menopause on IL-1 and IL-6 release from peripheral blood monocytes, J Bone Miner Res, 6, 76
- Thompson, 1991, IL-lra: Properties and uses of an interleukin-1 receptor antagonist, Agents Actions, 41
- Girasole, 1995, Increased serum soluble interleukin-6 receptor levels are induced by ovariectomy, prevented by estrogen replacement, and reversed by alendronate administration, J Bone Miner Res, 10, A86
- McKane, 1993, Effect of age and menopause on serum interleukin-1β and intereleukin-6- levels in women, J Bone Miner Res, 8, 162A
- Kimble, 1994, Long-term treatment with IL-1 receptor antagonist (IL-lra) blocks bone loss in ovariectomized rats, J Bone Miner Res, 9, B380
- Kimble, 1995, Inhibition of IL-6 activity is genetically normal mice does not prevent ovariectomy-induced bone loss, J Bone Miner Res, 10, s160
- Ammann, 1995, Transgenic mice expressing high levels of soluble tumor necrosis factor receptor-1 fusion protein are protected from bone loss caused by estrogen deficiency, J Bone Miner Res, 10
Cited by
Items 401–500 of 743
Nawaz, H., & Katz, D. L. (1999) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(99)00072-0 · Cited by 20
Jiang, Y., Xin, N., Yang, J., Wu, W., Wang, M., Feng, N., & Zhu, G. (2021) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2021.103719 · Cited by 19
FAEE exerts a protective effect against osteoporosis by regulating the MAPK signalling pathway
Wang, M., An, M., Fan, M., Zhang, S.-S., Sun, Z., Zhao, Y., Xiang, Z., & Sheng, J. (2022) · Pharmaceutical Biology · doi:10.1080/13880209.2022.2039216 · Cited by 19
Keqiang, L. I., Yu, H., Lin, X.-J., Su, Y., Gao, L., Song, M., Fan, H., Krokosz, D., Yang, H., & Lipowski, M. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8602753 · Cited by 27
“[2], which affect the stability of the lower limbs and increase the risk of fracture.”
BackgroundCao, H., Lei, S., Deng, H., & Wang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042755 · Cited by 19
“In the present study we selected circulating monocytes as our target cells because circulating monocytes serve as progenitors of osteoclasts [21]– [23], and secrete osteoclastogenic cytokines, such as IL-1, IL-6, and TNF-a [24]–[26].”
BackgroundSharifi, M., & Lewiecki, E. M. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.893819 · Cited by 20
“Bone loss occurs throughout the skeleton, but is typically most pronounced in the trabecular bone due to its greater surface area and higher rate of bone remodeling compared with the cortical bone [4,5]; there is also an age-related increase in bone marrow adiposity that may play a role in the differing rate of declin…”
BackgroundTsukazaki, H., Kikuta, J., Ao, T., Morimoto, A., Fukuda, C., Tsuda, E., Minoshima, M., Kikuchi, K., Kaito, T., & Ishii, M. (2021) · Bone · doi:10.1016/j.bone.2021.116095 · Cited by 19
Bone metabolism and the perimenopause
Sayegh, R. A., & Stubblefield, P. G. (2002) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(02)00012-8 · Cited by 26
Premenstrual exacerbations of multiple sclerosis
Zorgdrager, A., & Keyser, J. D. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.2.279 · Cited by 19
“Pathways through which sex steroids influence the immune system are complex and incompletely understood. Oestrogens may inhibit the release of Th1 cytokines, such as IL-1 and TNF-α, whereas progesterone may enhance the release of Th2 cytokines, which inhibit the production and activity of the Th1 cytokines.”
BackgroundMetabolic bone disease and total parenteral nutrition: a progress report
Jeejeebhoy, K. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.2.186 · Cited by 19
Yang, Y., & Dai, M. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2248 · Cited by 18
“It has been established that TNF-α acts as a stimulator of osteoclastogenesis (27-31) and an inhibitor of osteoblastogenesis (32-36).”
Estrogen Plus Estrogen Receptor Antagonists Alter Mineral Production by Osteoblasts In Vitro
Brennan, O., O’Brien, F. J., & McNamara, L. M. (2011) · Hormone and Metabolic Research · doi:10.1055/s-0031-1291358 · Cited by 21
Skeletal bone diseases impact the periodontium: a review of bisphosphonate therapy
Palomo, L., LIU, J. H., & Bissada, N. F. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.3.309 · Cited by 18
“Alveolar bone loss in periodontal disease, skeletal bone loss in postmenopausal osteoporosis, Paget’s disease and metastatic cancers are results of osteoclastic activity [1,2].”
BackgroundLee, J. S., Ryu, C. H., Moon, N. H., Kim, S., Park, S. Y., & Suh, K. T. (2008) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-008-0632-8 · Cited by 21
“Moreover, TNF- has been studied extensively in bone and has been implicated in the regulation of osteoclastogenesis [18].”
BackgroundEriksen, C. G., Olsen, H., Husted, L. B., Sørensen, L., Carstens, M., Søballé, K., & Langdahl, B. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9412-x · Cited by 20
“The cytokines and growth factors exert their regulatory effect on bone turnover by stimulation of proliferation and differentiation of bone cells and by influencing the secretion of growth factors and other mediators of cell communication [4–7].”
BackgroundAnsar, S., Alhefdhi, T., & Aleem, A. M. (2015) · PubMed · Cited by 18
Cytokine expression by cultured osteoblasts from patients with osteoporotic fractures
Walsh, ⁄., Birch, M., Fraser, W. D., Ginty, A., & Gallagher, J. A. (2000) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2000.00147.x · Cited by 19
“Pacifici (1996) has suggested that the integrated action of oestrogen-regulated cytokines in human bone cells may be significant in postmenopausal osteoporosis.”
BackgroundNordin, B. E. C. (1997) · Food, nutrition and agriculture · Cited by 40
Compston, J. E. (1997) · Baillière s Clinical Rheumatology · doi:10.1016/s0950-3579(97)80021-0 · Cited by 18
Cho, H., Lee, J., Jang, S., Lee, J. S., Oh, T. I., Son, Y., & Lee, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010325 · Cited by 17
“Cytokines such as IL-1 and IL-6, and growth factors such as TNF-α and TGF-β , RANKL, and OPG are involved in OB–OC coupling [31,32].”
Experimental techniques for screening of antiosteoporotic activity in postmenopausal osteoporosis
Satpathy, S., Patra, A., & Ahirwar, B. (2015) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2015-0034 · Cited by 17
Evaluation and management of skeletal disease in cancer care
Kommalapati, A., Tella, S. H., Esquivel, M. A., & Correa, R. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.003 · Cited by 19
“BMSCs-MM cells interaction express IL-6, Macrophage inflammatory protein 1a (MIP 1a), RANKL and M-CSF that promote osteoclastogenesis.”
BackgroundInfluentialTao, L., Huang, Q., Yang, R. R., Dai, Y., Zeng, Y., Li, C., Li, X., Zeng, J., & Wang, Q. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01004-0 · Cited by 19
Xu, L., Zheng, L., Wang, Z., Li, C. V., Li, S., Xia, X., Zhang, P., Li, L., & Zhang, L. (2018) · PubMed Central · doi:10.14348/molcells.2018.2359 · Cited by 17
“Inflammatory cytokines, especially TNF-α, affect the osteogenic differentiation of hMSCs and impair bone formation in osteoporosis (Pacifici, 1996; Sang et al., 2016).”
BackgroundZovari, F., Parsian, H., Bijani, A., Moslemnezhad, A., & Shirzad, A. (2020) · International Journal of Dentistry · doi:10.1155/2020/8860467 · Cited by 23
Osteoprotegerina y Sistema RANKL/RANK: ¿el futuro del metabolismo óseo?
Cañabate, J. F., Tovar, I., & Martínez, P. (2002) · Anales de Medicina Interna · doi:10.4321/s0212-71992002000800001 · Cited by 33
Tıkız, C., Ünlü, Z., Tıkız, H., Ay, K., Angın, A., Onur, E., Var, A., & Tüzün, Ç. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-004-0496-0 · Cited by 17
“Because many studies have shown that cytokines such as IL-1, IL-6, and TNF-α produced locally are involved in the regulation of bone remodeling, by inducing osteoclastic activity [35, 36 ] or bone formation [37], one of the main aims of the present study was to investigate the association between the bone turnover par…”
BackgroundAntineoplastic treatment effect on bone mineral density in Mexican breast cancer patients
Monroy-Cisneros, K., Esparza‐Romero, J., Valencia, M. E., Guevara-Torres, A. G., Estrada, R. O. M., Anduro-Corona, I., & Astiazarán‐García, H. (2016) · BMC Cancer · doi:10.1186/s12885-016-2905-x · Cited by 17
Simfia, I., Schiavi, J., & McNamara, L. M. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112005 · Cited by 18
L’ostéoporose : épidémiologie, clinique et approches thérapeutiques
Fontana, A., & Delmas, P. D. (2001) · médecine/sciences · doi:10.1051/medsci/200117121297 · Cited by 26
Abrahamsen, B., Stilgren, L. S., Rettmer, E., Bonnevie‐Nielsen, V., & Beck‐Nielsen, H. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-2037-y · Cited by 17
“These include ‘‘upstream’’ cytokines (IL-1b, TNF-a, IL-6 and IL-11) [2, 3] as well as ‘‘downstream’’ cytokines, [e.g., osteoprotegerin ligand (OPG-L; also known as TRANCE or RANKL)] and macrophage colony-stimulating factor (M-CSF) [4–6].”
Lindsay, R., & Cosman, F. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50070-2 · Cited by 21
Diagnostic biomarkers for periodontitis (observational case-control study)
Mohammed, A., Fadhil, R., Mahmood, M. S., & Al‐Waeli, H. (2024) · Journal of Baghdad College of Dentistry · doi:10.26477/jbcd.v36i2.3673 · Cited by 18
“…factor, and granulocyte-macrophage colony-stimulating factor, which produce bone resorption in alveolar bone, activate mature osteoclasts, control bone cell proliferation, and induce osteoclasts (21,22) , destroying collagen, in particular type 1 collagen, the main form of collagen in bones (23) .”
BackgroundThe Role of Exercise on Fracture Reduction and Bone Strengthening
KEMMLER, W. K., & von Stengel, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814593-7.00020-7 · Cited by 28
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance
Yin, M. T., & Shane, E. J. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/med.0b013e3280109b6c · Cited by 17
Scafonas, A., Reszka, A. A., Kimmel, D. B., Hou, X., Su, Q., Birzin, E. T., Kim, S., Chen, H. Y., Tan, Q., Roher, S. P., et al. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.10.013 · Cited by 17
Osteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0026-2 · Cited by 17
“In laboratory animals, estrogen deficiency is associated with enhanced osteoclastogenesis and this process can be reversed by estrogen, which restores the physiologic block that prevents excessive bone resorption by inducing small but cumulative changes in multiple estrogen-dependent regulatory factors [2,3, 31 ,32].”
BackgroundRogers, A., Clowes, J. A., Pereda, C. A., & Eastell, R. (2006) · Bone · doi:10.1016/j.bone.2006.07.011 · Cited by 18
“There is certainly an increase in proinflammatory cytokines (IL-1β, IL-6, TNFα, GM-CSF, MCSF, PGE2) in estrogen deficiency [1,10,11].”
BackgroundThe metabolic puzzle during the evolution of HIV infection
Salas‐Salvadó, J., & García‐Lorda, P. (2001) · Clinical Nutrition · doi:10.1054/clnu.2001.0429 · Cited by 17
Regulation of Bone Cell Function by Estrogens
Komm, B. S., & Bodine, P. V. N. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50011-8 · Cited by 17
Citrate: a key signalling molecule and therapeutic target for bone remodeling disorder
Liu, Q., Xue, Y., Guo, J., Tao, L., & Zhu, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1512398 · Cited by 17
Gaudio, A., Lasco, A., Morabito, N., Atteritano, M., Vergara, C., Catalano, A., Fries, W., Trifiletti, A., & Frisina, N. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03347549 · Cited by 17
Cytokines and fracture healing
Cho, T., Gerstenfeld, L. C., Barnes, G. B., & Einhorn, T. A. (2001) · Current Opinion in Orthopedics · doi:10.1097/00001433-200110000-00007 · Cited by 15
Osteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-996-0014-5 · Cited by 16
Dai, Y., & Shen, L. (2007) · Chinese Medical Journal · doi:10.1097/00029330-200711020-00015 · Cited by 15
Du, Y., Li, P., Wen, Y., Liang, X., Liu, L., Cheng, B., Ding, M., Zhao, Y., Ma, M., Zhang, L., et al. (2020) · Calcified Tissue International · doi:10.1007/s00223-019-00640-y · Cited by 14
Weiss, M. B., Syed, S. A., Whiteson, H. Z., Hirani, R., Etienne, M., & Tiwari, R. K. (2024) · Life · doi:10.3390/life14050561 · Cited by 16
“Both age-related and hormonal factors increase this risk, and the trauma-induced inflammatory response has itself been shown to increase bone resorption [106].”
BackgroundPingali, U., Nutalapati, C., & Wang, Y. (2025) · Journal of Menopausal Medicine · doi:10.6118/jmm.24025 · Cited by 18
“Aging is linked to chronic, low-grade systemic inflammation and oxidative stress, while the beneficial effects of oestrogen on bone and vascular endothelial function are partially due to its ability to reduce both inflammation and oxidative stress [7-10].”
Factor Analysis of Biochemical Markers Associated with Bone Mineral Density in Adults
Cho, J.-H., Kim, M., Lee, H.-K., Hong, I.-S., & Jang, H. (2014) · Journal of Physical Therapy Science · doi:10.1589/jpts.26.1225 · Cited by 14
Osteogenesis Hormonal Regulation: Review
Мироманов, А. М., & Аркадьевич, Г. К. (2021) · Traumatology and Orthopedics of Russia · doi:10.21823/2311-2905-1609 · Cited by 14
Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis
Zhao, N., Wei, W., Xu, Y., Li, D., Yin, B., & Gu, W. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0759 · Cited by 18
Park, J., Choi, M., Lee, S. H., Choi, Y., & Park, Y. K. (2011) · Journal of Nutrition and Health · doi:10.4163/kjn.2011.44.1.29 · Cited by 14
Bone remodelling in osteoarthrosic subjects undergoing a physical exercise program
Bellometti, S. A., Bertè, F., Richelmi, P., Tassoni, T., & Galzigna, L. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(02)00286-3 · Cited by 14
Gao, Y., Morita, I., Kubota, T., Murota, S., & Asô, T. (2000) · Climacteric · doi:10.1080/13697130008500123 · Cited by 16
Karakuş, E., Halıcı, Z., Albayrak, A., Bayır, Y., Demirci, E., Aydın, A., Öztürk, B., Çadırcı, E., Ayan, A. K., Sahin, A., et al. (2015) · Inflammation · doi:10.1007/s10753-015-0254-6 · Cited by 14
“Bone loss is prevented by estrogen, which affects bone marrow and bone cells, reduces osteoclast formation [31], increases osteoclast apoptosis [32], and decreases the capacity of mature osteoclasts to resorb bone [33].”
BackgroundEftekhari, H., Hosseini, S. R., Baboli, H. P., Golchin, M. M., Heidari, L., Abedian, Z., Pourbagher, R., Amjadi‐Moheb, F., Kani, S. N. M., Nooreddini, H., et al. (2018) · Gene · doi:10.1016/j.gene.2018.05.118 · Cited by 14
Bae, S., Shin, M. W., Son, T., Lee, H. S., Chae, J. S., Jeon, S., Oh, G. T., & Kim, K. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0201-3 · Cited by 16
TNFα receptor knockout in mice reduces adverse effects of magnesium deficiency on bone
Rude, R. K., Wei, L. Y., Norton, H. J., Lu, S. S., Dempster, D. W., & Gruber, H. E. (2009) · Growth Factors · doi:10.3109/08977190903152644 · Cited by 15
“Increased production of these cytokines has been implicated in the development of sex steroid deficiency or postmenopausal osteoporosis (Manolagas et al. 1995; Pacifici 1996).”
BackgroundOda, T., Wada, T., Kuwabara, H., Sawada, N., Yamashita, T., & Kokai, Y. (2005) · Journal of Orthopaedic Science · doi:10.1007/s00776-004-0851-y · Cited by 14
Radzki, R. P., Bieńko, M., Wolski, D., Oniszczuk, T., Radzka-Pogoda, A., Polak, P., Borzęcki, A., & Stasiak, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112467 · Cited by 13
Bone Disease in Elderly Individuals With CKD
Kansal, S. K., & Fried, L. F. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.05.001 · Cited by 13
A case of pandysautonomia with associated sensory ganglionopathy
KUROKAWA, K., NODA, K., Mimori, Y., WATANABE, C., Katayama, S., NAKAMURA, S., Sannomiya, K., Yamamoto, S., & Tahara, E. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.2.278 · Cited by 14
Jin, G., Aobulikasimu, A., Piao, J., Aibibula, Z., Koga, D., Sato, S., Ochi, H., Tsuji, K., Nakabayashi, T., Miyata, T., et al. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12390 · Cited by 13
Nordin, B. E. C. (1997) · Osteoporosis International · doi:10.1007/bf03194337 · Cited by 13
“This prevailing view rests on direct evidence of an action of oestrogen on bone mediated by cytokines [48] and on the perceived superiority of oestrogen over calcium in the prevention and treatment of postmenopausal osteoporosis.”
BackgroundHLA alleles as predisposal factors for postmenopausal osteoporosis in a Greek population
Douroudis, K., Tarassi, K., Athanassiades, T., Giannakopoulos, F., Kominakis, A., Thalassinos, N. C., & Papasteriades, C. (2007) · Tissue Antigens · doi:10.1111/j.1399-0039.2007.00833.x · Cited by 12
Giaze, T. R., Shuid, A. N., Soelaiman, I. N., Muhammad, N., Jamal, J. A., Fauzi, M. B., & Mohamed, N. (2019) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2019.01.002 · Cited by 12
Roux, S., & Brown, J. P. (2009) · Current Rheumatology Reviews · doi:10.2174/157339709788298428 · Cited by 16
“These cells produce bone-resorbing factors in the bone microenvironment such as IL-1, IL-6, TNF , M-CSF or GM-CSF, that may be downregulated by estrogens [66].”
BackgroundUnderstanding osteoclast formation and function: implications for future therapies for osteoporosis
Zaidi, M., Moonga, B. S., Sun, L., Epstein, S., Huang, C. L.-H., & Abe, E. (2003) · Current Opinion in Orthopedics · doi:10.1097/00001433-200310000-00007 · Cited by 12
Lossdörfer, S., Götz, W., & Jäger, A. (2002) · Cytokine · doi:10.1006/cyto.2002.1970 · Cited by 15
Interleukin-1 receptor antagonist [IL-1F3]
Arend, W. P., & EVANS, C. (2003) · Elsevier eBooks · doi:10.1016/b978-012689663-3/50032-6 · Cited by 15
Jin, Y., Lee, M., & Park, Y. (2017) · British Journal Of Nutrition · doi:10.1017/s0007114517000344 · Cited by 11
“Previous studies have shown that E2 treatment reduced osteoclastogenesis through stimulation of OPG secretion but decreased RANKL and cytokine expressions((5,6,20)), consistent with the present study.”
ResultThe role of metabolites under the influence of genes and lifestyles in bone density changes
Lv, X., Jiang, Y., Yang, D., Zhu, C., Yuan, H., Yuan, Z., Suo, C., Chen, X., & Xu, K. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.934951 · Cited by 11
“Previous studies have shown that under the plant-based diet, there is a risk of decreased BMD and an increased probability of fractures (25, 26).”
BackgroundImpact of seborrheic dermatitis on osteoporosis risk: A population‐based cohort study
Lu, Y., Lu, C., Tsai, C., Liu, Y., Huang, C., Wang, W., & Wu, C. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16578 · Cited by 11
Wang, L., Ye, C., Zhao, F., Wu, H., Wang, R., Zhang, Z., & Li, J. (2023) · JMIR Public Health and Surveillance · doi:10.2196/43501 · Cited by 12
“This may be due to a significant change in estrogen levels after menopause in women who are prone to osteoporosis and an increase in the risk of fractures [62,63].”
BackgroundPutra, H. L. (2011) · Universitas Airlangga Repository (Universitas Airlangga) · Cited by 11
Dynamic expression of SMAD3 is critical in�osteoblast differentiation of PDMCs
Lin, H., Chen, S., Guo, J., Su, I., Huang, C., Chien, C., & Chang, C. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.4001 · Cited by 12
“For example, bone loss in older people due to imbalances between osteoblast and osteoclast activitymay servea role in post-fracture mortality (11,12).”
Effect of pre-treatment of strength training and raloxifene in periestropause on bone healing
Peres-Ueno, M. J., Fernandes, F. B., Brito, V. G. B., de Nicola, A. C., Stringhetta-Garcia, C. T., Castoldi, R. C., Menezes, A. R. P., Ciarlini, P. C., Louzada, M. J. Q., Oliveira, S. H. P., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115285 · Cited by 11
Is the negative relationship between obesity and bone mineral content greater for older women?
Chung, W., Lee, J., & Ryu, O. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0519-9 · Cited by 11
“Also, adipocytes secrete inflammatory cytokines, including interleukin6 and, tumor necrosis factor-a, which affect bone resorption and bone loss [39, 40].”
BackgroundCamacho‐Alonso, F., Martínez-Ortiz, C., Plazas-Buendía, L., Mercado‐Díaz, A. M., Vilaplana‐Vivo, C., Navarro, J. A., Buendía, A. J., Merino, J. J., & Beneyto, Y. M. (2020) · Clinical Oral Investigations · doi:10.1007/s00784-019-03180-9 · Cited by 11
Shim, K., Hwang, Y., Jang, S., Kim, T. S., & Ha, H. (2020) · Nutrients · doi:10.3390/nu12071927 · Cited by 11
Osteoporosis in a patient with recessive dystrophic epidermolysis bullosa
Kawaguchi, M., Mitsuhashi, Y., & Kondo, S. (1999) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1999.03178.x · Cited by 11
Proliferative Response of Different Human Osteoblast-like Cell Models to Proinflammatory Cytokines
Harbour, M. E., Gregory, J. W., Jenkins, H. R., & Evans, B. A. J. (2000) · Pediatric Research · doi:10.1203/00006450-200008000-00008 · Cited by 11
Lambertini, E., Penolazzi, L., Sollazzo, V., Pezzetti, F., de Mattei, M., SENNO, L. D., Traina, G., & Piva, R. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720683 · Cited by 11
Clinical experience with a 7-day estrogen patch: Principles and practice
Notelovitz, M. (1998) · Gynecological Endocrinology · doi:10.3109/09513599809015597 · Cited by 11
Low Bone Mineral Density, HIV Infection, and Women: Fracture or Fiction?
Yin, M. T., & Glesby, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/501025 · Cited by 11
LPL-RH suppresses bone loss in ovariectomised rat models
Chen, W., Wang, X.-L., Wang, Y., Liu, D., Yue, M., Wei, J., Li, J., Chen, T., & Tu, H. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03683-w · Cited by 10
“The primary significant pathophysiology of PMOP is abnormal bone reabsorption mediated by hyperactive osteoclast, specialised macrophage differentiated from osteoclast precursors when stimulated by M-CSF and RANKL [9, 10].”
Desai, M. P., Khatkhatay, M. I., Taskar, V., & Ansari, Z. (2012) · Intern J Endocrinol Metab · doi:10.5812/ijem.3339 · Cited by 12
Imauchi, Y., Lainé, P., Sterkers, O., Ferrary, É., & Grayeli, A. B. (2004) · Acta Oto-Laryngologica · doi:10.1080/00016480310017081 · Cited by 10
“Estrogens have been widely used as a treatment for postmenopausal osteoporosis, with evidence of in vivo efficacy, but their precise mechanisms of action remain unclear (10).”
BackgroundInfluentialIL-1αand IL-1βLevels in Blood Serum and Saliva of Menopausal Women
Rahnama, M., Jastrzębska, I., Jamrogiewicz, R., & Kocki, J. (2012) · Endocrine Research · doi:10.3109/07435800.2012.713425 · Cited by 10
“Fibroblasts are also a source of many cytokines (7).”
BackgroundKaleta, B., Walicka, M., Sawicka, A., Bogołowska-Stieblich, A., Górski, A., Łukaszkiewicz, J., & Marcinowska-Suchowierska, E. (2015) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/22747 · Cited by 10
New Target Sites for Treatment of Osteoporosis
Müller, W. E. G., Wang, X., & Schröder, H. C. (2017) · Progress in molecular and subcellular biology · doi:10.1007/978-3-319-51284-6_6 · Cited by 13
Rugo, H. S. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.s.003 · Cited by 10
Løbo, R. A. (2007) · Elsevier eBooks · doi:10.1016/b978-0-323-02951-3.50045-5 · Cited by 11
Transcriptional regulation of collagenase‐3 by interleukin‐1 alpha in osteoblasts
Varghese, S., & CANALIS, E. M. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10732 · Cited by 10
“Key words: cytokines; matrix metalloproteinase-13; RNA stabilization; procollagenase; prostaglandins Cytokines, such as interleukin-1 (IL-1)a and b, are present in the bone microenvironment and are found to be important regulators of skeletal tissue [Pacifici, 1996].”
BackgroundEstrogen Receptors Critically Regulate Bones’ Adaptive Responses to Loading
Lanyon, L. E., Armstrong, V. J., Saxon, L., Sunters, A., Sugiyama, T., Zaman, G., & Price, J. S. (2007) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-008-9011-9 · Cited by 12
“The primary effects of estrogen on the skeleton have traditionally been recognised as stimulation of closure of the growth plates (reviewed in [23]), inhibition of periosteal expansion [24, 25], reduced activation frequency of remodelling units [26–28], apoptosis of osteoclasts [29, 30] and inhibition of apoptosis in…”
BackgroundPacifici, R. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50042-8 · Cited by 10
Self-citationMolecular Cross-Talk Between Nuclear Receptors and Nuclear Factor-κB
Beck, I. M. E., Haegeman, G., & Bosscher, K. D. (2010) · Springer eBooks · doi:10.1007/978-90-481-9531-2_10 · Cited by 9
Song, X., Shen, L., Contreras, J. M., Liu, Z., Ma, K., Ma, B., Liu, X., & Wang, D. O. (2024) · Phytotherapy Research · doi:10.1002/ptr.8289 · Cited by 10
“Increases OPG secretion (Przerwa et al., 2023) and decreases M-CSF (Pacifici, 1996) and RANK (Zhang et al., 2007) levels, inhibiting bone resorption or the release of calcium from bones that results in decreased bone mass [130 – 132] Genitalia tissue Reduces the thinning of vaginal mucosa (Rahn et al., 2014) [133] tis…”
Knee deformity in rheumatoid arthritis is closely correlated with generalized osteoporosis
Kikkawa, T., Okano, T., Hagino, H., Otsuki, R., Katagiri, H., & Teshima, R. (2008) · Modern Rheumatology · doi:10.3109/s10165-007-0018-8 · Cited by 9
Positive relation between dietary inflammatory index and osteoporosis in postmenopausal women
Mohammadisima, N., Farshbaf‐Khalili, A., Ostadrahimi, A., & Pourmoradian, S. (2022) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000773 · Cited by 10
Metadata
- Authors
- Pacifici, R.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Pacifici, Roberto
- ORCID
- Pacifici, Roberto
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-08-01
- Volume
- 11
- Issue
- 8
- Pages
- 1043-1051
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2110993073
- Cited by
- 741
- References
- 90
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 15 · 2023: 20 · 2022: 20 · 2021: 24 · 2020: 20 · 2019: 26 · 2018: 30 · 2017: 15 · 2016: 19 · 2015: 31 · 2014: 29 · 2013: 22 · 2012: 28
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag013534-04)
- National Institute on Aging (AG 13534)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR041412, AR41412)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- postmenopausal osteoporosis, estrogen deficiency, cytokines, interleukin-1, TNF-α, bone resorption, osteoclastogenesis, osteoclast apoptosis, bone marrow, cytokine synergy, estrogen withdrawal, cytokine inhibitors
- MeSH terms
- Animals, Bone and Bones, Bone Resorption, Estrogens, Female, Humans, Menopause, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.